M A Hoffman1, J A Blessing, M Morgan. 1. Division of Hematology-Oncology, Long Island Jewish Medical Center, New Hyde Park, New York 11040, USA.
Abstract
OBJECTIVES: The objectives of this study were twofold: (1) to estimate the anti-tumor efficacy of CI-958 in patients with measurable platinum-resistant ovarian cancer; (2) to determine the nature and degree of toxicity of CI-958 in these patients. METHODS: Patients received CI-958 560 mg/m(2) intravenously every 3 weeks and tumor measurements were performed every one to two cycles. RESULTS: In 25 cases with recurrent platinum-resistant disease, there was one partial response (PR) and six patients had stable disease (SD). CONCLUSIONS: CI-958 has minimal activity in platinum-resistant ovarian cancer at the dose and schedule tested. Copyright 2000 Academic Press.
OBJECTIVES: The objectives of this study were twofold: (1) to estimate the anti-tumor efficacy of CI-958 in patients with measurable platinum-resistant ovarian cancer; (2) to determine the nature and degree of toxicity of CI-958 in these patients. METHODS:Patients received CI-958 560 mg/m(2) intravenously every 3 weeks and tumor measurements were performed every one to two cycles. RESULTS: In 25 cases with recurrent platinum-resistant disease, there was one partial response (PR) and six patients had stable disease (SD). CONCLUSIONS:CI-958 has minimal activity in platinum-resistant ovarian cancer at the dose and schedule tested. Copyright 2000 Academic Press.
Authors: Kian Behbakht; Michael W Sill; Kathleen M Darcy; Stephen C Rubin; Robert S Mannel; Steven Waggoner; Russell J Schilder; Kathy Q Cai; Andrew K Godwin; R Katherine Alpaugh Journal: Gynecol Oncol Date: 2011-07-12 Impact factor: 5.482
Authors: Lydia Usha; Michael W Sill; Kathleen M Darcy; Doris M Benbrook; Jean A Hurteau; David P Michelin; Robert S Mannel; Parviz Hanjani; Koen De Geest; Andrew K Godwin Journal: Gynecol Oncol Date: 2011-03-17 Impact factor: 5.482
Authors: David S Miller; John A Blessing; Carolyn N Krasner; Robert S Mannel; Parviz Hanjani; Michael L Pearl; Steven E Waggoner; Cecelia H Boardman Journal: J Clin Oncol Date: 2009-03-30 Impact factor: 44.544